{"doc_id": "33486496", "type of study": "Therapy", "title": "", "abstract": "Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial.\nThere is still no clinical evidence available to support or to oppose corticosteroid treatment for coronavirus disease 2019 (COVID-19) pneumonia.\nTo investigate the efficacy and safety of corticosteroid given to the hospitalized patients with COVID-19 pneumonia.\nThis was a prospective, multicenter, single-blind, randomized control trial.\nAdult patients with COVID-19 pneumonia who were admitted to the general ward were randomly assigned to either receive methylprednisolone or not for 7 days.\nThe primary end point was the incidence of clinical deterioration 14 days after randomization.\nWe terminated this trial early because the number of patients with COVID-19 pneumonia in all the centers decreased in late March.\nFinally, a total of 86 COVID-19 patients underwent randomization.\nThere was no difference of the incidence of clinical deterioration between the methylprednisolone group and control group (4.8 vs. 4.8%, p = 1.000).\nThe duration of throat viral RNA detectability in the methylprednisolone group was 11 days (interquartile range, 6-16 days), which was significantly longer than that in the control group (8 days [2-12 days], p = 0.030).\nThere were no significant differences between the 2 groups in other secondary outcomes.\nMass cytometry discovered CD3+ T cells, CD8+ T cells, and NK cells in the methylprednisolone group which were significantly lower than those in the control group after randomization (p < 0.05).\nFrom this prematurely closed trial, we found that the short-term early use of corticosteroid could suppress the immune cells, which may prolong severe acute respiratory syndrome coronavirus 2 shedding in patients with COVID-19 pneumonia.\nTRIAL REGISTRATION : ClinicalTrials.gov, NCT04273321.\n\u00a9 2021 S. Karger AG, Basel.\n", "Evidence Map": {"Enrollment": [{"term": "Non-Intensive Care Unit Patients", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 95}, {"term": "COVID-19 Pneumonia", "negation": "affirmed", "UMLS": {}, "start": 101, "end": 119}, {"term": "hospitalized patients", "negation": "affirmed", "UMLS": {}, "start": 70, "end": 91}, {"term": "COVID-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 115}, {"term": "Adult patients", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 14}, {"term": "COVID-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 20, "end": 38}, {"term": "admitted", "negation": "affirmed", "UMLS": {}, "start": 48, "end": 56}, {"term": "general ward", "negation": "affirmed", "UMLS": {}, "start": 64, "end": 76}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 24, "end": 32}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia : A Multicenter , Single-Blind , Randomized Control Trial .", "Evidence Elements": {"Participant": [{"term": "Non-Intensive Care Unit Patients", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 95}, {"term": "COVID-19 Pneumonia", "negation": "affirmed", "UMLS": {}, "start": 101, "end": 119}], "Intervention": [{"term": "Corticosteroid", "negation": "affirmed", "UMLS": {}, "start": 13, "end": 27, "has_chemical": [{"text": "corticosteroid", "maps_to": "C3536709:Corticosteroid", "start": 0, "end": 14}], "has_relation": "N/A"}], "Outcome": [{"term": "SARS-CoV-2 Shedding", "negation": "affirmed", "UMLS": {}, "start": 40, "end": 59}], "Observation": [{"term": "Prolong", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 39}], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "There is still no clinical evidence available to support or to oppose corticosteroid treatment for coronavirus disease 2019 ( COVID-19 ) pneumonia .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "OBJECTIVE", "Text": "To investigate the efficacy and safety of corticosteroid given to the hospitalized patients with COVID-19 pneumonia .", "Evidence Elements": {"Participant": [{"term": "hospitalized patients", "negation": "affirmed", "UMLS": {}, "start": 70, "end": 91}, {"term": "COVID-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 115}], "Intervention": [{"term": "corticosteroid", "negation": "affirmed", "UMLS": {}, "start": 42, "end": 56, "has_chemical": [{"text": "corticosteroid", "maps_to": "C3536709:Corticosteroid", "start": 0, "end": 14}], "has_relation": "N/A"}], "Outcome": [{"term": "efficacy", "negation": "affirmed", "UMLS": {}, "start": 19, "end": 27}, {"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 38}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "This was a prospective , multicenter , single-blind , randomized control trial .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Adult patients with COVID-19 pneumonia who were admitted to the general ward were randomly assigned to either receive methylprednisolone or not for 7 days .", "Evidence Elements": {"Participant": [{"term": "Adult patients", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 14}, {"term": "COVID-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 20, "end": 38}, {"term": "admitted", "negation": "affirmed", "UMLS": {}, "start": 48, "end": 56}, {"term": "general ward", "negation": "affirmed", "UMLS": {}, "start": 64, "end": 76}], "Intervention": [{"term": "methylprednisolone", "negation": "affirmed", "UMLS": {}, "start": 118, "end": 136, "has_chemical": [{"text": "methylprednisolone", "maps_to": "C0025815:methylprednisolone", "start": 0, "end": 18}], "has_relation": "N/A"}, {"term": "not", "negation": "negated", "UMLS": {}, "start": 140, "end": 143, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary end point was the incidence of clinical deterioration 14 days after randomization .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "incidence of clinical deterioration", "negation": "affirmed", "UMLS": {}, "start": 30, "end": 65}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "We terminated this trial early because the number of patients with COVID-19 pneumonia in all the centers decreased in late March .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "number of patients with COVID-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 43, "end": 85}], "Observation": [{"term": "decreased", "negation": "affirmed", "UMLS": {}, "start": 105, "end": 114}], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Finally , a total of 86 COVID-19 patients underwent randomization .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 24, "end": 32}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "There was no difference of the incidence of clinical deterioration between the methylprednisolone group and control group ( 4.8 vs . 4.8 % , p = 1.000 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "methylprednisolone", "negation": "negated", "UMLS": {}, "start": 79, "end": 97, "has_chemical": [{"text": "methylprednisolone", "maps_to": "C0025815:methylprednisolone", "start": 0, "end": 18}], "has_relation": "N/A"}, {"term": "control", "negation": "negated", "UMLS": {}, "start": 108, "end": 115, "has_relation": "N/A"}], "Outcome": [{"term": "incidence of clinical deterioration", "negation": "negated", "UMLS": {}, "start": 31, "end": 66}], "Observation": [{"term": "difference", "negation": "negated", "UMLS": {}, "start": 13, "end": 23}, {"term": "4.8", "negation": "negated", "UMLS": {}, "start": 124, "end": 127}, {"term": "4.8 %", "negation": "affirmed", "UMLS": {}, "start": 133, "end": 138}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "methylprednisolone", "has_chemical": [{"text": "methylprednisolone", "maps_to": "C0025815:methylprednisolone", "start": 0, "end": 18}], "has_relation": "N/A"}, {"term": "control", "has_relation": "N/A"}], "Observation": "difference", "Outcome": "incidence of clinical deterioration", "Count": ""}, {"Intervention": {"term": "methylprednisolone", "has_chemical": [{"text": "methylprednisolone", "maps_to": "C0025815:methylprednisolone", "start": 0, "end": 18}], "has_relation": "N/A"}, "Observation": "4.8", "Outcome": "incidence of clinical deterioration", "Count": ""}, {"Intervention": {"term": "control", "has_relation": "N/A"}, "Observation": "4.8 %", "Outcome": "incidence of clinical deterioration", "Count": ""}]}, {"Section": "RESULTS", "Text": "The duration of throat viral RNA detectability in the methylprednisolone group was 11 days ( interquartile range , 6-16 days ) , which was significantly longer than that in the control group ( 8 days [ 2-12 days ] , p = 0.030 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "methylprednisolone", "negation": "affirmed", "UMLS": {}, "start": 54, "end": 72, "has_chemical": [{"text": "methylprednisolone", "maps_to": "C0025815:methylprednisolone", "start": 0, "end": 18}], "has_relation": "N/A"}, {"term": "control", "negation": "affirmed", "UMLS": {}, "start": 177, "end": 184, "has_relation": "N/A"}], "Outcome": [{"term": "duration of throat viral RNA detectability", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 46}], "Observation": [{"term": "11 days", "negation": "affirmed", "UMLS": {}, "start": 83, "end": 90}, {"term": "significantly longer", "negation": "affirmed", "UMLS": {}, "start": 139, "end": 159}, {"term": "8 days", "negation": "affirmed", "UMLS": {}, "start": 193, "end": 199}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "methylprednisolone", "has_chemical": [{"text": "methylprednisolone", "maps_to": "C0025815:methylprednisolone", "start": 0, "end": 18}], "has_relation": "N/A"}, "Observation": "11 days", "Outcome": "duration of throat viral RNA detectability", "Count": ""}, {"Intervention": [{"term": "methylprednisolone", "has_chemical": [{"text": "methylprednisolone", "maps_to": "C0025815:methylprednisolone", "start": 0, "end": 18}], "has_relation": "N/A"}, {"term": "control", "has_relation": "N/A"}], "Observation": "significantly longer", "Outcome": "duration of throat viral RNA detectability", "Count": ""}, {"Intervention": {"term": "control", "has_relation": "N/A"}, "Observation": "8 days", "Outcome": "duration of throat viral RNA detectability", "Count": ""}]}, {"Section": "RESULTS", "Text": "There were no significant differences between the 2 groups in other secondary outcomes .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "2 groups", "negation": "negated", "UMLS": {}, "start": 50, "end": 58, "has_relation": "N/A"}], "Outcome": [{"term": "other secondary outcomes", "negation": "negated", "UMLS": {}, "start": 62, "end": 86}], "Observation": [{"term": "significant differences", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 37}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "2 groups", "has_relation": "N/A"}], "Observation": "significant differences", "Outcome": "other secondary outcomes", "Count": ""}]}, {"Section": "RESULTS", "Text": "Mass cytometry discovered CD3+T cells , CD8+T cells , and NK cells in the methylprednisolone group which were significantly lower than those in the control group after randomization ( p < 0.05 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "methylprednisolone", "negation": "affirmed", "UMLS": {}, "start": 74, "end": 92, "has_chemical": [{"text": "methylprednisolone", "maps_to": "C0025815:methylprednisolone", "start": 0, "end": 18}], "has_relation": "N/A"}, {"term": "control", "negation": "affirmed", "UMLS": {}, "start": 148, "end": 155, "has_relation": "N/A"}], "Outcome": [{"term": "CD3+T cells", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 37}, {"term": "CD8+T cells", "negation": "affirmed", "UMLS": {}, "start": 40, "end": 51}, {"term": "NK cells", "negation": "affirmed", "UMLS": {}, "start": 58, "end": 66}], "Observation": [{"term": "significantly lower", "negation": "affirmed", "UMLS": {}, "start": 110, "end": 129}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "methylprednisolone", "has_chemical": [{"text": "methylprednisolone", "maps_to": "C0025815:methylprednisolone", "start": 0, "end": 18}], "has_relation": "N/A"}, {"term": "control", "has_relation": "N/A"}], "Observation": "significantly lower", "Outcome": "CD3+T cells", "Count": ""}, {"Intervention": [{"term": "methylprednisolone", "has_chemical": [{"text": "methylprednisolone", "maps_to": "C0025815:methylprednisolone", "start": 0, "end": 18}], "has_relation": "N/A"}, {"term": "control", "has_relation": "N/A"}], "Observation": "significantly lower", "Outcome": "NK cells", "Count": ""}]}, {"Section": "CONCLUSIONS", "Text": "From this prematurely closed trial , we found that the short-term early use of corticosteroid could suppress the immune cells , which may prolong severe acute respiratory syndrome coronavirus 2 shedding in patients with COVID-19 pneumonia .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "short-term early use of corticosteroid", "negation": "affirmed", "UMLS": {}, "start": 55, "end": 93, "has_chemical": [{"text": "corticosteroid", "maps_to": "C3536709:Corticosteroid", "start": 24, "end": 38, "has_duration": ["short term"]}], "has_relation": "N/A"}], "Outcome": [{"term": "immune cells", "negation": "affirmed", "UMLS": {}, "start": 113, "end": 125}, {"term": "severe acute respiratory syndrome coronavirus 2 shedding", "negation": "affirmed", "UMLS": {}, "start": 146, "end": 202}], "Observation": [{"term": "suppress", "negation": "affirmed", "UMLS": {}, "start": 100, "end": 108}, {"term": "prolong", "negation": "affirmed", "UMLS": {}, "start": 138, "end": 145}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "short-term early use of corticosteroid", "has_chemical": [{"text": "corticosteroid", "maps_to": "C3536709:Corticosteroid", "start": 24, "end": 38, "has_duration": ["short term"]}], "has_relation": "N/A"}, "Observation": "suppress", "Outcome": "immune cells", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "TRIAL REGISTRATION : ClinicalTrials.gov , NCT04273321 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "\u00a9 2021 S . Karger AG , Basel .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}